Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants.
Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). CIOF is associated with menopausal symptoms, fertility concerns and long-term implications including bone loss. Ironically, CIOF might confer a disease-specific benefit to women whose breast cancers express hormone receptors. Risk factors of CIOF include the woman's age at the time of therapy, and the type, dose and schedule of chemotherapy. Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions.
Stearns
Vered
V
Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. vstearn1@jhmi.edu
Schneider
Bryan
B
Henry
N Lynn
NL
Hayes
Daniel F
DF
Flockhart
David A
DA
D001943:Breast Neoplasms / Q000150:complications / Q000235:genetics / Q000628:therapy*; D005260:Female; D006801:Humans; D017697:Premenopause; D016649:Primary Ovarian Insufficiency / Q000209:etiology / Q000235:genetics* / Q000517:prevention & control; D012307:Risk Factors